Haloperidol oral im

Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D 2 receptor antagonism and slow receptor dissociation kinetics. [41] It has effects similar to the phenothiazines . [17] The drug binds preferentially to D 2 and α 1 receptors at low dose (ED 50 = and  mg/kg, respectively), and 5-HT 2 receptors at a higher dose (ED 50 =  mg/kg). Given that antagonism of D 2 receptors is more beneficial on the positive symptoms of schizophrenia and antagonism of 5-HT 2 receptors on the negative symptoms, this characteristic underlies haloperidol's greater effect on delusions, hallucinations and other manifestations of psychosis. [42] Haloperidol's negligible affinity for histamine H 1 receptors and muscarinic M 1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms .

CNS depression potentiated with alcohol, other CNS depressants. Possible neurotoxicity with lithium: monitor, discontinue if occurs. Caution with drugs that prolong the QT interval (eg, ketoconazole, paroxetine). May be potentiated by CYP3A4 or CYP2D6 inhibitors/substrates (eg, itraconazole, nefazodone, buspirone, venlafaxine, alprazolam, fluvoxamine, quinidine, fluoxetine, sertraline, chlorpromazine, promethazine. May be antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine); monitor and adjust doses. May increase intraocular pressure with anticholinergics, antiparkinson agents. Monitor anticoagulants.

<1%, postmarketing, and/or case reports: Abnormal hepatic function tests, acneiform eruption, acute hepatic failure, agitation, agranulocytosis, akathisia, alopecia, amenorrhea, anaphylaxis, anemia, blurred vision, bronchopneumonia, bronchospasm, cardiac arrhythmia, cholestasis, cogwheel rigidity, confusion, decreased libido, depression, dizziness, dyskinesia, dysmenorrhea, dyspnea, edema, erectile dysfunction, exfoliative dermatitis, extrasystoles, facial edema, galactorrhea, gynecomastia, heatstroke, hepatic insufficiency, hepatitis, hyperammonemia, hyperhidrosis, hyperprolactinemia, hyperpyrexia, hypersensitivity angiitis, hypersensitivity reaction, hypertension, hyperthermia, hypoglycemia, hypokinesia, hypotension, hypothermia, injection site reaction, insomnia, jaundice, laryngeal edema, laryngospasm, leukocytosis, leukopenia, lymphocytosis with monocytosis, maculopapular rash, mask-like face, mastalgia, menorrhagia, motor dysfunction, muscle rigidity, muscle twitching, nausea, neonatal withdrawal, neuroleptic malignant syndrome, neutropenia, nystagmus, opisthotonus, orthostatic hypotension, pancytopenia, priapism, prolonged Q-T interval on ECG, pruritus, restlessness, rhabdomyolysis, sedation, seizure, SIADH, skin photosensitivity, skin rash, tachycardia, tardive dyskinesia, tardive dystonia, thrombocytopenia, torsades de pointes, torticollis, trismus, urinary retention, urticaria, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, vomiting, weight gain, weight loss

3 to 12 years and 15 to 40 kg :
-Initial dose: mg/day orally in 2 to 3 divided doses
-Maintenance dose: to mg/kg/day

Comments :
-The daily dose may be increased every 5 to 7 days in mg increments.
-There is little evidence that behavior improvement is further enhanced by doses greater than 6 mg/day.
-Limitation of use: Treatment should be reserved for patients with severe behavior problems and/or hyperactive children only after failure to respond to psychotherapy or medications (other than antipsychotics).

Uses :
-Treatment of severe behavior problems in children, including combative, explosive hyperexcitability not accounted for by immediate provocation
-Short-term treatment of hyperactive children with excessive motor activity and accompanying conduct disorder with impulsivity, difficulty sustaining attention, aggressiveness, mood lability, and/or poor frustration tolerance.

Haloperidol oral im

haloperidol oral im

3 to 12 years and 15 to 40 kg :
-Initial dose: mg/day orally in 2 to 3 divided doses
-Maintenance dose: to mg/kg/day

Comments :
-The daily dose may be increased every 5 to 7 days in mg increments.
-There is little evidence that behavior improvement is further enhanced by doses greater than 6 mg/day.
-Limitation of use: Treatment should be reserved for patients with severe behavior problems and/or hyperactive children only after failure to respond to psychotherapy or medications (other than antipsychotics).

Uses :
-Treatment of severe behavior problems in children, including combative, explosive hyperexcitability not accounted for by immediate provocation
-Short-term treatment of hyperactive children with excessive motor activity and accompanying conduct disorder with impulsivity, difficulty sustaining attention, aggressiveness, mood lability, and/or poor frustration tolerance.

Media:

haloperidol oral imhaloperidol oral imhaloperidol oral imhaloperidol oral imhaloperidol oral im

http://buy-steroids.org